Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Rating) shares reached a new 52-week high on Thursday following a better than expected earnings announcement. The stock traded as high as $81.00 and last traded at $71.99, with a volume of 32651 shares traded. The stock had previously closed at $75.89.
The medical equipment provider reported $0.89 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.25. Lantheus had a positive return on equity of 19.83% and a negative net margin of 6.89%. The company had revenue of $223.80 million for the quarter, compared to the consensus estimate of $204.51 million. During the same quarter in the previous year, the business earned $0.11 earnings per share. The company’s revenue for the quarter was up 121.4% on a year-over-year basis.
Analyst Upgrades and Downgrades
A number of equities research analysts have commented on the company. B. Riley assumed coverage on Lantheus in a research report on Monday, May 9th. They issued a “buy” rating and a $91.00 target price on the stock. Truist Financial boosted their price objective on Lantheus from $77.00 to $94.00 in a report on Monday, May 2nd. Finally, SVB Leerink boosted their price objective on Lantheus from $100.00 to $110.00 and gave the company an “outperform” rating in a report on Friday.
Insider Activity at Lantheus
Institutional Investors Weigh In On Lantheus
Several large investors have recently bought and sold shares of the stock. Financial Gravity Asset Management Inc. purchased a new stake in Lantheus during the 2nd quarter worth about $2,319,000. Nia Impact Advisors LLC acquired a new position in shares of Lantheus during the 2nd quarter worth about $1,718,000. Hanseatic Management Services Inc. boosted its position in shares of Lantheus by 7,396.5% during the 2nd quarter. Hanseatic Management Services Inc. now owns 8,621 shares of the medical equipment provider’s stock worth $569,000 after acquiring an additional 8,506 shares in the last quarter. Los Angeles Capital Management LLC acquired a new position in shares of Lantheus during the 2nd quarter worth about $730,000. Finally, Convergence Investment Partners LLC acquired a new position in shares of Lantheus during the 2nd quarter worth about $201,000. Hedge funds and other institutional investors own 97.14% of the company’s stock.
Lantheus Trading Up 10.3 %
The company has a 50-day moving average price of $67.85 and a 200-day moving average price of $55.56. The firm has a market capitalization of $5.39 billion, a price-to-earnings ratio of -137.84 and a beta of 0.79. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.64 and a current ratio of 1.83.
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.
- Get a free copy of the StockNews.com research report on Lantheus (LNTH)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.